Search

Your search keyword '"Wynn, D."' showing total 203 results

Search Constraints

Start Over You searched for: Author "Wynn, D." Remove constraint Author: "Wynn, D."
203 results on '"Wynn, D."'

Search Results

5. A Learning Center Approach to Learning in Adult Basic Education.

6. Survey of Ak Chin Indian Reservation to Determine Educational Needs. Final Report.

7. POLICIES OF EDUCATIONAL NEGOTIATION PROBLEMS AND ISSUES. RESEARCH MONOGRAPH.

11. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

17. Phase III Dose-Comparison Study of Glatiramer Acetate for Multiple Sclerosis

18. Liraglutide and Renal Outcomes in Type 2 Diabetes

19. A Cooking Curriculum.

20. The Washington District School Volunteer Program.

21. ASSESSMENT OF A GRADUATE LEVEL SELF-TEACHING TECHNIQUE BASED ON A COMBINATION OF PROGRAMED INSTRUCTION AND THE CASE METHOD.

22. Focus on the Kindergarten. Early Childhood Education Series 1.

24. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

25. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

26. daclizumab in active relapsing multiple clerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

27. Health-related quality of life in multiple sclerosis: Effects of natalizumab

28. ПРЕИМУЩЕСТВА РАННЕГО НАЧАЛА ЛЕЧЕНИЯ ГЛАТИРАМЕРА АЦЕТАТОМ (КОПАКСОН®): РЕЗУЛЬТАТЫ МРТ-ОБСЛЕДОВАНИЯ, ПОЛУЧЕННЫЕ В 5-ЛЕТНЕМ ПРОСПЕКТИВНОМ НАБЛЮДЕНИИ ПАЦИЕНТОВ С КЛИНИЧЕСКИ ИЗОЛИРОВАННЫМ СИНДРОМОМ, ВКЛЮЧЕННЫХ В ИССЛЕДОВАНИЕ PRECISE

30. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis

31. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL

32. The incidence and significance of anti-natalizumab antibodies. Results from the AFFIRM and SENTINEL

33. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

40. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis

49. THE THERAPY OF REINVENTION.

50. Rebif® Quality of Life (RebiQoL): A randomized, multicenter, Phase IIIb study evaluating quality-of-life measures in patients receiving the serum-free formulation of subcutaneous interferon beta-1a for the treatment of relapsing forms ...

Catalog

Books, media, physical & digital resources